of arthritis. No effective disease-modifying agents for OA have yet been identified though phase 2 and 3 trials are underway, and, for the time being, preventive strategies focus on weight management and injury prevention. Development of more effective therapies that permit a sophisticated and individualized approach to the patient with OA await the outcome of future investigation. Important directions for research include gaining a more comprehensive understanding of the optimal types of